IP Group PLC 2025 AR2
The report highlights IP Group plc's return to Net Asset Value (NAV) growth in 2025, with NAV per share increasing by 13% to 110.4p and a closing NAV of £975.1m. A major driver was the recognition of £128.2m in discounted future royalty and milestone income from Pfizer's acquisition of Metsera. The company also achieved £68.1m in cash proceeds from exits, including the successful IPO of Hinge Health on the NYSE and the sale of Monolith to CoreWeave. Additionally, IP Group completed its £75m share buyback programme, retiring 9% of its share capital during the year.
Company: IP Group PLC
Sector: Financials
Country: United Kingdom
Year: 2025
Type: AR2
Pages: 174
IP Group PLC
Annual Report And Accounts
The report highlights IP Group plc's return to Net Asset Value (NAV) growth in 2025, with NAV per share increasing by 13% to 110.4p and a closing NAV of £975.1m. A major driver was the recognition of £128.2m in discounted future royalty and milestone income from Pfizer's acquisition of Metsera. The company also achieved £68.1m in cash proceeds from exits, including the successful IPO of Hinge Health on the NYSE and the sale of Monolith to CoreWeave. Additionally, IP Group completed its £75m share buyback programme, retiring 9% of its share capital during the year.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Women on Board
Women in Management
Net Zero Target
Employees